E-Books durchsuchen
Molecules Engineered Against Oncogenic Proteins and Cancer [2023]
- 1
-
Introduction
- 18
-
BCR‐ABL Inhibitors
- 43
-
BTK Inhibitors
- 59
-
EGFR/HER Family Inhibitors
- 97
-
VEGFR/Multikinase Inhibitors
- 127
-
CDK4/6 Inhibitors
- 144
-
JAK Inhibitors
- 187
-
Allosteric TYK2 Inhibitors
- 195
-
ALK/multikinase Inhibitors
- 214
-
BRAF/Multikinase Inhibitors
- 227
-
MEK Inhibitors
- 240
-
RET/Multikinase Inhibitors
- 253
-
FGFR Inhibitors
- 267
-
PI3K Inhibitors
- 284
-
TRK/Multikinase Inhibitors
- 294
-
MET Inhibitors
- 299
-
KIT/PDGFR/Multikinase Inhibitors
- 306
-
FLT3 Inhibitors
- 315
-
mTOR Inhibitors
- 322
-
Other Kinase Inhibitors
- 335
-
KRAS Inhibitors
- 353
-
An Overview of the Discovery Process for Medically Useful Inhibitors of Oncogenic Protein Kinases
- 368
-
Targeted Molecular Anticancer Therapies – Successes and Challenges
- 374
-
Appendix 1: First FDA Approvals by Year
- 375
-
Appendix 2: Kinase/KRAS Inhibitors in Development <sup>1,2</sup>
- 378
-
Appendix 3: Visualization of Differentially Expressed Kinases in Cancer <sup>1,2</sup>
- 379
-
Appendix 4: M&A Transactions Driven by Oncology‐focused Kinase and KRAS inhibitors <sup>1,2</sup>
- 380
-
Appendix 5: Alphabetic List of Oncogenic Protein Inhibitors
- i
-
Front Matter
